CLAIMS

What is claimed is

1. Use of a HPV vaccine composition in the manufacture of a medicament for treatment of a cancer in a patient, wherein the cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, melanoma, skin cancer, and HPV-associated cancerous tumor or lesion, wherein :

    a) a first dose of the HPV vaccine composition which is free of host-cell peptide, polypeptide, or protein or a degradant product thereof is to be administered to a patient 27 years of age or older or a patient previously not immunized with an HPV vaccine;

    b) a second dose of the HPV vaccine composition is to be administered to the patient in one month to three months after the first administration; and

    c) a third dose of the HPV vaccine composition is to be administered to the patient in five months to seven months after the first dose.

2. The use according to claim 1 wherein the second dose of HPV vaccine is to be administered in two months after the first dose is to be administered and the third dose of HPV vaccine is to be administered in six months after the first dose is to be administered.

3. The use according to claim 1 wherein the HPV vaccine is selected from the group consisting of HPV quadrivalent (types 6, 11, 16, and 18) recombinant vaccine comprising HPV L1 proteins and HPV multivalent (types 16, 18, 31, 33, 45, 52, and 58) recombinant vaccine comprising HPV L1 proteins.

4. The use according to claim 1 wherein the vaccine is substantially free of host-cell early antigen, E6 or E7.

5. The use according to claim 1 wherein the treatment does not comprise or excludes an additional or other immunostimulant or adjuvant to be administered.

6. The use according to claim 1 wherein the size of the cancer is substantially reduced.

7. The use according to claim 1 wherein the cancer is eliminated.

8. The use according to claim 1 whereby the incidence of recurrence of the cancer is reduced.

9. The use according to claim 1 wherein each dose of the HPV vaccine is 0.5 ml.

10. The use according to claim 1 characterized by

establishing a positive diagnosis of cancer prior to the first dose of HPV vaccine to be administered.

11. Use of a HPV vaccine composition in the manufacture of a medicament for the treatment of a cancer in a patient, wherein the cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, melanoma, skin cancer, and HPV-associated cancerous tumor or lesion, wherein:

a) a first dose of the HPV vaccine composition is to be administered directly to the cancer site or an area immediately surrounding the cancer site; and

b) a second dose of the HPV vaccine composition is to be administered in two months after the first dose is to be administered and a third dose of the HPV vaccine composition is to be administered in six months after the first dose is to be administered.

12. The use according to claim 11, further comprising:

c) the second dose of the HPV vaccine composition to be administered directly to the cancer site or an area immediately surrounding the cancer site in one month to three months after the first dose is to be administered; and

d) optionally, the third dose of the HPV vaccine composition to be administered directly to the cancer site or an area immediately surrounding the cancer site in five months to seven months after the first dose is to be administered.

13. The use according to claim 11 wherein the cancer is eliminated or substantially reduced in size.

14. The use according to claim 11 whereby the incidence of recurrence of the cancer is reduced.

15. The use according to claim 11 wherein the dose of the HPV vaccine administered is 0.5 ml.

16. The use according to claim 11 characterized by

establishing a positive diagnosis of cancer prior to the first dose of the HPV vaccine to be administered.

17. The use according to claim 11 wherein the vaccine is to be administered by injection.

18. The use according to claim 11 wherein the treatment does not comprise or excludes an additional or other immunostimulant or adjuvant to be administered.

19. Use of a HPV vaccine composition in the manufacture of a medicament for the treatment of a cancer in a patient, wherein the cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, melanoma, skin cancer, and HPV-associated cancerous tumor or lesion, wherein:

a) a first dose of the HPV vaccine composition comprising at least one viral L1 protein which is free of non-L1 viral peptide, polypeptide, or protein or a degradant product thereof is to be administered to a patient having squamous cell carcinoma, basal cell carcinoma, melanoma, skin cancer, HPV-associated cancerous tumor, or HPV-associated cancerous tumor or lesion, and being 27 years of age or older or a patient previously not immunized with a HPV vaccine;

b) a second dose of the HPV vaccine composition is to be administered to the patient in one month to three months after the first administration; and

c) a third dose of the HPV vaccine composition is to be administered to the patient in five months to seven months after the first dose.

20. The use according to claim 19 wherein the second dose of HPV vaccine is to be administered in two months after the first dose is to be administered and the third dose of HPV vaccine is to be administered in six months after the first dose is to be administered.

21. The use according to claim 19 wherein the HPV vaccine is selected from the group consisting of HPV quadrivalent (types 6, 11, 16, and 18) recombinant vaccine comprising HPV L1 proteins and HPV multivalent recombinant vaccine comprising HPV L1 proteins of HPV types 16, 18, 31, 33, 45, 52, and 58.

22. The use according to claim 19 wherein the treatment does not comprise or excludes a second composition comprising an immunostimulant or an adjuvant to be administered.

23. Use of a HPV vaccine composition in the manufacture of a medicament for the treatment of a cancer in a patient, wherein the cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, melanoma, skin cancer, and HPV-associated cancerous tumor or lesion, wherein:

a) a first dose of the HPV vaccine composition is to be administered to a patient with squamous cell carcinoma, basal cell carcinoma, melanoma, skin cancer, HPV-associated cancerous tumor, or HPV-associated cancerous tumor or lesion, wherein administration is directly into said squamous cell carcinoma, basal cell carcinoma, melanoma, skin cancer, HPV-associated cancerous tumor or lesion; and

b) a second dose of the HPV vaccine composition is to be administered in two months after the first dose is to be administered and a third dose of the HPV vaccine composition is to be administered in six months after the first dose is to be administered.

24. The use according to claim 23, further comprising:

c) the second dose of the HPV vaccine composition to be administered directly to the squamous cell carcinoma, basal cell carcinoma, melanoma, skin cancer, HPV-associated cancerous tumor or lesion, in one month to three months after the first dose is to be administered; and

d) optionally, the third dose of the HPV vaccine composition to be administered directly to said squamous cell carcinoma, basal cell carcinoma, melanoma, skin cancer, HPV-associated cancerous tumor or lesion in five months to seven months after the first dose is to be administered.

25. The use according to claim 23 wherein the squamous cell carcinoma, basal cell carcinoma, melanoma, skin cancer, HPV-associated cancerous tumor, and HPV-associated cancerous tumor or lesion is eliminated or substantially reduced in size.

26. The use according to claim 23 whereby recurrence of cancer is reduced.

27. The use according to claim 23 wherein the vaccine is to be administered by injection.

28. The use according to claim 23 wherein the treatment does not comprise or excludes to be administered a second composition comprising an immunostimulant or adjuvant.